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Abstract: Malawi adopted the Option B+ strategy in 2011. Its
success in reducing mother-to-child transmission depends on coverage
and timing of HIV testing. We assessed HIV status ascertainment and
its predictors during pregnancy. HIV status ascertainment was 82.3%
(95% conﬁdence interval: 80.2 to 85.9) in the pre-Option B+ period
and 85.7% (95% conﬁdence interval: 83.4 to 88.0) in the Option B+
period. Higher HIV ascertainment was independently associated with
higher age, attending antenatal care more than once, and registration in
2010. The observed high variability of HIV ascertainment between
sites (50.6%–97.7%) and over time suggests that HIV test kit
shortages and insufﬁcient numbers of staff posed major barriers to
reducing mother-to-child transmission.
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BACKGROUND
UNAIDS and other agencies have called for the virtual
elimination of mother-to-child transmission (EMTCT) of
HIV. The 2011 global EMTCT plan1 established strategies
for accomplishing this goal and requires that 90% of all HIV-
positive women have access to antiretroviral therapy (ART),
so that new infections can be reduced to ,5%. But, in many
African countries, far fewer than 90% of pregnant women are
tested for HIV. In Malawi, just more than 70% of pregnant
women had their HIV status ascertained during antenatal care
(ANC) in 2010.2 Many women are tested for the ﬁrst time
during pregnancy, and HIV testing rates vary substantially
between settings.3
Until August 2011, pregnant HIV-positive women in
Malawi were managed under the 2006 World Health
Organization (WHO) prevention of mother-to-child trans-
mission guidelines. These guidelines recommended women
with a CD4 count $350 cells per microliter and women in
WHO stages 1 and 2 to start on antiretroviral prophylaxis in
the third trimester (28 weeks). Lifelong ART was only
recommended for women with a CD4 cell count ,350 cells
per microliter and those in WHO stages 3 or 4.
In September 2011, Malawi was the ﬁrst country to
introduce the Option B+ strategy, which calls for lifelong
ART for all pregnant and breastfeeding women, irrespective
of CD4 count and clinical status.4 Option B+ is intended to
streamline access to treatment and care for HIV-positive
women, but its success depends on testing a sufﬁcient
percentage of pregnant women. We sought to determine the
coverage, timing, and predictors of HIV testing among
pregnant Malawian women who attended ANC.
METHODS
The prevention of mother-to-child transmission ser-
vice cascade starts at the ANC clinic, which is usually part
of an integrated maternal and child health service. On
registration at the clinic, a woman’s baseline data, including
age, parity, gravidity, gestational age, treatment history,
preventive medicines (ie, tetanus vaccine and malaria pro-
phylaxis), and previous HIV test results, are recorded in
paper-based registers. Follow-up data are recorded at every
visit thereafter and include HIV testing status, preventive
medications, and body weight. Each woman is followed for
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6 months from registration, after which ANC outcomes are
determined. During this follow-up period, the woman is
expected to make at least 4 scheduled visits. ART data are
collected in paper-based registers at smaller health facilities
while facilities with more than 2500 patients use an
electronic medical record system.5
Our primary measure was HIV ascertainment among
pregnant women who attended ANC between January 1,
2010, and March 31, 2014, in Southern and Central Malawi.
We included all sites that had an electronic medical record
ART system in April 2011, the time when data entry started.
Women were classiﬁed as HIV negative if their records
included a negative HIV test within the last 3 months before
the antenatal visit. They were classiﬁed HIV positive if their
record showed a positive HIV test or if there was written
evidence that they were on ART. Secondary outcomes were
gestational age at the ﬁrst ANC visit, percentage of women
tested for HIV during the ﬁrst trimester among all women
who attended ANC, and percentage of HIV-positive women
among all women whose HIV status had been ascertained.
We analyzed individual records of HIV tests extracted from
the paper-based ANC registers for the pre-Option B+ period
(January 1, 2010, until June 30, 2011) and aggregated
facility data for the whole time period (January 1, 2010, until
March 2014).
We entered the individual-level ANC records into an
electronic database. We calculated, by facility, the percent-
age of women whose HIV status had been ascertained and
combined the results in a random-effect meta-analysis.
Among women whose HIV status was unknown at ANC
initiation, we calculated, for each facility, the percentage
that was given rapid HIV tests. The percentage of women
tested at clinics with at least 10 ANC attendees was
calculated for each week. We used univariable and multi-
variable random-effect logistic regression models to iden-
tify demographic and facility-level characteristics
associated with ascertaining HIV status. We considered
the following variables: age (,20, 20–34, and $35 years);
parity (0, 1, and .1); gestational age at the ﬁrst ANC visit
(ﬁrst trimester versus thereafter); number of ANC visits
(1 and .1); and year of ANC registration (2010 and 2011).
We also included the following facility-level character-
istics: facility location (urban and rural); zone (central east,
central west, southeast, and southwest); type of facility
(health center, Christian Health Association of Malawi
hospital, district hospital, and central hospital); and the
mean number of women registered at ANC per month
(,300 and $300 women). We did a complete case analysis
and an analysis with multiple imputations. Missing data
concerning gestational age, HIV ascertainment, parity, and
age were imputed using multiple imputation with chained
equations.6 We imputed values dependent on HIV ascer-
tainment, parity category, gestational age category, and the
other predictor variables from the multivariable analysis.
We created 15 imputed datasets and combined results using
Rubin’s rule.7
We used the aggregated facility-level data to compare
the proportion of women with ascertained HIV status during
the pre-Option B+ and the Option B+ period.
The National Health Sciences Research Committee
granted ethical approval for the study (approval number
962). All data analyses were performed with STATA
software (version 13.1, Stata Corp, College Station, TX).
RESULTS
A total of 100,515 women from 19 sites were included in
the individual-level data analysis and 194,345 women from the
same sites were included in the aggregated data analysis. There
were 13 district hospitals, 3 Christian Health Association of
Malawi hospitals, 2 central hospitals, and 1 health center. Five
of the 19 sites were located in urban areas, whereas other 5 sites
served more than 300 new ANC women every month. Five
sites were located in the central-west zone, 4 in the central-east
zone, 6 in the southeast zone, and 4 in the southwest zone.
Individual-Level Data
The characteristics of these women are shown in Table 1.
Only few women (5641; 5.6%) made their ﬁrst antenatal visit in
the ﬁrst trimester (ranged from 1.6% to 14.7% between
facilities). We had missing data of 5370 women (5.3%) on
HIV ascertainment, 10,254 (10.2%) on gestational age at the
ﬁrst ANC visit, and 3319 (3.3%) on parity.
HIV status was ascertained for 82,714 (82.3%) of
women, but this percentage varied widely across sites, from
50.6% to 97.7%. In 8 of the 19 facilities (42.1%), at least 90%
of women had their HIV status ascertained during pregnancy.
Most of the women (70,879; 85.7%) whose HIV status was
ascertained had no previous valid HIV test result at the start of
ANC and thus took a rapid HIV test, but the percentage
ranged from 55.0% to 99.0% between facilities. Among
women with known HIV status, 12.8% (10,596 of 82,714)
were HIV positive; this percentage varied from 1.4% to
19.5% between facilities.
Table 1 shows the predictors of HIV ascertainment of
the imputed analyses. In the unadjusted analysis, the likeli-
hood of ascertained HIV status increased with age, parity,
and the number of ANC visits. There was no difference
between women who started ANC during the ﬁrst trimester
and those who started later. Women who were registered in
2011 were less likely to have ascertained HIV status. Health
facilities in urban areas, that were health centers, located in
southern zones, and that had $300 women registered per
month were less likely to have high ascertained levels than
health facilities in rural areas, located in central zones, that
were not health centers, and that served ,300 women per
month. In multivariable analyses, age, registration year, and
number of ANC visits remained independently associated
with HIV ascertainment.
Figure 1 top panel shows weekly percentages of women
whose HIV status was unknown at their ﬁrst ANC visit and
who were subsequently tested during pregnancy.
The proportion of women tested during pregnancy
declined over time. In many facilities, testing rates ﬂuctuated
widely, and there were often weeks in which almost no
women were tested. In only 1 site, there was HIV testing
coverage .90% throughout the whole period examined.
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Aggregated-Level Data
Aggregated-level data show that HIV ascertainment did
not improve in the Option B+ period, whereas it was 82.3%
(95% conﬁdence interval: 80.2 to 85.9) in the pre-Option B+
period and was 85.7% (95% conﬁdence interval: 83.4 to 88.0)
in the B+ period (Fig. 1; lower panel).
DISCUSSION
We found that EMTCT goal of ascertaining the HIV
status of at least 90% of all pregnant women at ANC clinics
was not reached in Malawi between 2010 and 2014. Over this
period of 51 months, the overall rate of HIV ascertainment
was 84.8% and did not change signiﬁcantly since the
introduction of Option B+. Ascertainment rates varied widely
between sites and ﬂuctuated tremendously in sites over short
time periods. Before Option B+, only 16% of facilities
reached or exceeded the target of 90% of testing women
with unknown status, but only 1 facility reached 90% every
week. Women were more likely to have ascertained HIV
status if they were older, registered in 2010, and if they made
more than 1 antenatal visit.
Our data suggest that important barriers to achieving the
EMTCT goal exist at the facility level. We observed sudden
TABLE 1. Patients and Facility Characteristics Associated With HIV Status Ascertainment Among Pregnant Women Attending ANC






N % OR (95% CI) P OR (95% CI) P
Clinic burden, women/mo
#300 50,252 87.4 1 ,0.001 1 0.928
.300 50,263 77.2 0.45 (0.43 to 0.47) 0.78 (0.21 to 2.91)
Facility type
Health center 7470 50.6 1 ,0.001 1 0.155
CHAM hospital 10,738 82.2 2.94 (2.72 to 3.19) 1.44 (0.12 to 16.86)
District hospital 75,062 84.4 2.69 (2.54 to 2.85) 2.39 (0.26 to 22.19)
Central hospital 7245 92.7 11.25 (9.66 to 13.11) 8.61 (0.61 to 121.43)
Gestational age at ﬁrst visit, wks
#12 5641 80.7 1 0.481 1 0.605
.12 84,620 81.1 1.03 (0.95 to 1.12) 0.98 (0.89 to 1.07)
Unknown 10,254 92.6
Parity
Never given birth 26,195 81.9 1 0.008 0.825
1 birth 21,911 82.2 1.00 (0.94 to 1.05) 1.00 (0.93 to 1.07)
.1 births 49,090 83.1 1.06 (1.01 to 1.11) 0.98 (0.92 to 1.05)
Unknown 3319 74.5
Age, yrs
,20 19,219 81.2 1 ,0.001 1 0.005
20–35 69,371 83.0 1.15 (1.10 to 1.21) 1.10 (1.03 to 1.17)
.35 7278 84.4 1.21 (1.12 to 1.32) 1.15 (1.04 to 1.28)
Unknown 4647 73.6
Registration year
2011 65,084 77.2 1 ,0.001 1 ,0.001
2010 35,431 85.1 1.67 (1.61 to 1.73) 1.77 (1.70 to 1.85)
Facility location
Rural 34,983 84.0 1 0.516 1 0.745
Urban 65,532 79.0 1 (0.99 to 1.02) 0.77 (0.17 to 3.60)
Health area zone
Central east 15,922 87.1 1 ,0.001 1 0.947
Central west 38,465 86.3 0.89 (0.83 to 0.95) 0.99 (0.28 to 3.48)
Southeast 29,301 82.3 0.54 (0.50 to 0.57) 1.34 (0.34 to 5.36)
Southwest 16,827 68.7 0.46 (0.43 to 0.50) 0.95 (0.26 to 3.46)
No. ANC visits
1 27,164 71.1 1 ,0.001 1 ,0.001
.1 73,351 86.4 2.38 (2.29 to 2.47) 2.65 (2.54 to 2.77)
Adjusted for all variables are shown in this table.
CHAM, Christian Health Association of Malawi; CI, conﬁdence interval; OR, odds ratio.
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decreases over time in the number of women who received
a new HIV test, and this is in line with previous ﬁndings that
showed that temporary shortages of test kit supplies and staff
interrupt regular testing of women for HIV during pregnancy.8–11
Unfortunately, adequate data about the availability of HIV test
kits and staff during the period were not available.
Several studies have shown that social and individual
factors are associated with low rates of HIV testing. Low
uptake of HIV testing has been associated with single
motherhood, low level of education, lower socioeconomical
class, late ANC attendance, and fewer ANC visits.3,4,12–16 We
also found that women who had more than 1 ANC visit were
more likely to have an ascertained HIV status than those who
made a single visit probably because multiple visits increased
the chance to attend when materials and testing staff were
available. Consistent with ﬁndings in the Malawi Demo-
graphic Health Survey of 2010, we found that women
younger than 20 years were less likely to have known HIV
status than older women.17
The large number of participants and the diverse group
of facilities across the whole country of Malawi allowed us to
examine many factors in parallel that can inﬂuence HIV
ascertainment. Our study also has a number of limitations: If
women registered more than once, we would have been
unable to identify this. We lacked access to socioeconomic
information while this can determine HIV testing status
importantly. We had incomplete data on gestational age,
age, parity, and HIV testing; however, similar results of the
analysis with multiple imputations and the complete case
analysis in multivariable modeling suggest that this did not
affect outcomes importantly. We were also limited by our
inability to determine why individual women were not tested.
A Malawian study from 2005 showed that 4.5% of women
refused pretest counseling, saying that they wanted to get
their husband’s consent and then never coming back.18 We
restricted our study to women who attended ANC in a health
facility because all but 3% of pregnant women attend ANC17;
an unknown proportion of women ﬁrst present only in
maternity or during delivery.
CONCLUSIONS
The current level of HIV testing uptake among pregnant
women in Malawi is too low to reach the EMTCT targets and
FIGURE 1. Upper panel: Proportion of
women with unknown HIV status tested
at their first ANC visit (n = 70,879/
88,680*); *11,835 women with previous
HIV test results have been excluded from
the denominator. Lower panel: Percent-
age of women with ascertained HIV sta-
tus by quarter for pre-Option B+ (solid)
and Option B+ (dash) periods. w1, first
week of the year; q1, first quarter of the
year (January–March).
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the millennium development goals, and this rate needs to be
improved to attain the full beneﬁts that the Option B+ strategy
potentially offers. The reasons why some facilities consis-
tently have high ascertainment rates must be determined by
future research. Potential barriers such as HIV test kit
shortages and an inadequate number of trained staff at clinics
need to be tackled with high priority.
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